U.S. life sciences company Illumina is in talks with EU antitrust regulators to divest Grail ahead of an EU veto next week on its $7.1 billion acquisition of the biotechnology company, people familiar with the matter said.
The European Commission is set to block the deal because remedies offered by Illumina do not fully address the EU competition enforcer's concerns, other sources told Reuters last month.
Illumina completed its takeover of Grail in August last year without waiting for the EU green light, and was subsequently ordered by the EU watchdog to keep Grail separate and install independent managers to run the company until a regulatory decision on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.